Suppr超能文献

纤维蛋白和D - 二聚体与单体糖蛋白VI结合。

Fibrin and D-dimer bind to monomeric GPVI.

作者信息

Onselaer Marie-Blanche, Hardy Alexander T, Wilson Clare, Sanchez Ximena, Babar Amir K, Miller Jeanette L C, Watson Callum N, Watson Stephanie K, Bonna Arkadiusz, Philippou Helen, Herr Andrew B, Mezzano Diego, Ariëns Robert A S, Watson Steve P

机构信息

Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

Thrombosis and Tissue Repair Group, Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

出版信息

Blood Adv. 2017 Aug 15;1(19):1495-1504. doi: 10.1182/bloodadvances.2017007732. eCollection 2017 Aug 22.

Abstract

Fibrin has recently been shown to activate platelets through the immunoglobulin receptor glycoprotein VI (GPVI). In the present study, we show that spreading of human platelets on fibrin is abolished in patients deficient in GPVI, confirming that fibrin activates human platelets through the immunoglobulin receptor. Using a series of proteolytic fragments, we show that D-dimer, but not the E fragment of fibrin, binds to GPVI and that immobilized D-dimer induces platelet spreading through activation of Src and Syk tyrosine kinases. In contrast, when platelets are activated in suspension, soluble D-dimer inhibits platelet aggregation induced by fibrin and collagen, but not by a collagen-related peptide composed of a repeat GPO sequence or by thrombin. Using surface plasmon resonance, we demonstrate that fibrin binds selectively to monomeric GPVI with a K of 302 nM, in contrast to collagen, which binds primarily to dimeric GPVI. These results establish GPVI as the major signaling receptor for fibrin in human platelets and provide evidence that fibrin binds to a distinct configuration of GPVI. This indicates that it may be possible to develop agents that selectively block the interaction of fibrin but not collagen with the immunoglobulin receptor. Such agents are required to establish whether selective targeting of either interaction has the potential to lead to development of an antithrombotic agent with a reduced effect on bleeding relative to current antiplatelet drugs.

摘要

最近研究表明,纤维蛋白可通过免疫球蛋白受体糖蛋白VI(GPVI)激活血小板。在本研究中,我们发现,缺乏GPVI的患者体内,人血小板在纤维蛋白上的铺展作用消失,这证实了纤维蛋白通过免疫球蛋白受体激活人血小板。利用一系列蛋白水解片段,我们发现,D - 二聚体而非纤维蛋白的E片段可与GPVI结合,并且固定化的D - 二聚体通过激活Src和Syk酪氨酸激酶诱导血小板铺展。相反,当血小板在悬浮液中被激活时,可溶性D - 二聚体可抑制由纤维蛋白和胶原蛋白诱导的血小板聚集,但不抑制由重复GPO序列组成的胶原相关肽或凝血酶诱导的血小板聚集。利用表面等离子体共振技术,我们证明,与主要结合二聚体GPVI的胶原蛋白不同,纤维蛋白以302 nM的解离常数选择性地结合单体GPVI。这些结果确定了GPVI是人血小板中纤维蛋白的主要信号受体,并提供证据表明纤维蛋白与GPVI的一种独特构象结合。这表明,有可能开发出选择性阻断纤维蛋白而非胶原蛋白与免疫球蛋白受体相互作用的药物。需要这类药物来确定,选择性靶向这两种相互作用中的任何一种是否有可能开发出一种抗血栓药物,相对于目前的抗血小板药物,其对出血的影响较小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/220f/5728468/243ec433aee6/advances007732absf1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验